glp-1 neuroendocrine tumor Dillon 1 Glucagon-like peptide 1 receptor agonists
Description
However, these drugs have been designed to treat type 2 diabetes, not CNS diseases [203,204,205]
It gets in the way of their ability to eat in a way that they would prefer for their health
The evidence for GLP-1 therapy in lupus is limited
The sudden onset of these gallbladder issues in patients taking GLP-1 drugs has prompted many to question the completeness of the manufacturers' safety information
